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Background: Topical tacrolimus is an effective anti-in-
flammatory therapy for acute and chronic states of atopic der-
matitis (AD) in both adults and children. Topical tacrolimus 
has particular use at sensitive areas such as the face, anogen-
itals, and skin folds of neck and extremities. However, many 
AD patients also experience aggravated symptoms on trunk. 
Objective: The aim of this study was to investigate the effi-
cacy and safety of topical tacrolimus for AD patients with 
truncal lesions. Methods: AD patients with truncal lesions 
who were aged ≥2 years were recruited from 20 centres in 
Korea. They received treatment with topical tacrolimus oint-
ment twice daily during 4 weeks. The primary end point was 
change of the local eczema area and severity index (EASI) of 
the trunk from baseline to day 28. The secondary end points 
were changes in the patient global assessment (PGA) score 
and itch visual analogue scale (VAS) score of the trunk be-
tween baseline and day 28. Results: Two hundred and nine-
ty-one patients were recruited, and 176 patients completed 
the full 4-week treatment course. By the end of the treatment, 
the mean local EASI of the trunk (2.2±4.71) was significantly 
decreased from that at baseline (4.71±4.03, p＜0.001). PGA 
(1.71±1.15) and itch VAS score of the trunk (2.61±2.19) on 
day 28 were also profoundly decreased compared with the 
baseline (2.96±1.07 and 5.15±2.47, respectively). No seri-
ous adverse events were observed during the study period. 
Conclusion: Topical tacrolimus is an effective and safe ther-
apy for truncal lesions in AD patients. (Ann Dermatol 30(2) 
173∼178, 2018)
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INTRODUCTION
Atopic dermatitis (AD) is a chronically relapsing, common 
inflammatory skin disease1. Topical corticosteroids are the 
mainstay treatment of AD. However, they carry the risk of 
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local side effects such as the development of skin atrophy, 
telangiectasia, acne, and striae, and systemic side effects 
that result from the suppression of the hypothalamic-pitui-
tary-adrenal axis, especially in cases with long-term use. 
Indeed, topical mid- to high-potency corticosteroids are 
difficult to use regularly on the face and intertriginous 
areas because of the local side effects2. For the above-men-
tioned reasons, topical tacrolimus has been particularly 
used at sensitive areas such as the face, anogenitals, and 
skin folds of neck and extremities, where the risk of the 
adverse effects of topical corticosteroids is higher3. Although 
many AD patients also experience aggravated symptoms 
in the truncal area4, only few studies have assessed the ef-
ficacy and safety of tacrolimus ointment for the treatment 
of AD on the truncal area. 
MATERIALS AND METHODS
Patients
AD patients with truncal lesions who were aged ≥2 years 
were recruited from 20 centres in Korea. AD was diag-
nosed in accordance with the criteria of Hanifin and 
Rajka5. Patients with truncal lesions affecting ＞1% of 
body surface area were selected. The exclusion criteria ap-
plied at recruitment were history of topical tacrolimus 
therapy within the previous 4 weeks, active infection, ma-
lignancy or uncontrolled chronic illness, pregnancy or nur-
sing state, immunosuppressed state, any serious skin dis-
order, and presence of contraindication to topical tacroli-
mus (e.g., skin ulcer, hypersensitivity to tacrolimus). 
Written informed consent was obtained from the partic-
ipant, and if age is under 18, from the parent or legal 
guardian.
The present study was approved by the institutional re-
view board of Pusan National University Yangsan Hospital 
(IRB no. 04-2015-006), The Catholic University of Korea, 
Incheon St. Mary’s Hospital (IRB no. OIRB-00243-007), 
Soonchunhyang University Bucheon Hospital (IRB no. 
SCHBC 2015-03-003), Wonju Severance Christian Hospital 
(IRB no. CR115003-005), Korea University Ansan Hospital 
(IRB no. AS14189-002), Kyung Hee University Hospital at 
Gangdong (IRB no. KHNMC 2015-02-030-001), Konkuk 
University Medical Center (IRB no. KUH1120064), 
Chungnam National University Hospital (IRB no. CNUH 
2015-06-039-003), The Catholic University of Korea, St. 
Vincent’s Hospital (IRB no. VIRB-00124-001), Samsung 
Changwon Hospital (IRB no. 2015-SCMC-027-00), Chosun 
University Hospital (IRB no. CHOSUN 2015-03-011), 
Asan Medical Center (IRB no. 2015-0662), Dongguk 
University Ilsan Hospital (IRB no. 2015-32), Severance 
Hospital (IRB no. 4-2015-0037), Gachon University Gil 
Medical Center (IRB no. GCIRB2015-110), The Catholic 
University of Korea, Seoul St. Mary’s Hospital (IRB no. 
KC15MIMI0221), Kyungpook National University Hospital 
(IRB no. KNUH 2015-03-038-002), Chonbuk National 
University Hospital (IRB no. CUH 2015-03-030-001), 
Ajou University Hospital (IRB no. AJIRB-MED-OBS-15- 
046), Hallym University Kangnam Sacred Heart Hospital 
(IRB no. 2015-02-21), Korea.
Study design
Tacrolimus ointment 0.1% (for patients aged ≥19 years) 
and 0.03% (for patients aged ＜19 years) were applied 
twice daily to all areas of active disease. The amounts of 
topical tacrolimus ointment applied to AD lesions were 
measured in fingertip units6,7. The treatment was con-
tinued for 4 weeks, regardless of whether complete clear-
ance in all baseline treatment areas had been achieved. 
The patients were prohibited to receive either systemic or 
topical corticosteroids, or immunosuppressive drugs or 
phototherapy (ultraviolet [UV] A, UVB) or antibiotics, ex-
cept in the case of controlling infected AD with topical an-
tibiotics, herbal remedy, γ-linolenic acid, and other drugs 
in the investigation during the study. The patients were 
permitted to take oral antihistamines and to use non-medi-
cated emollients as needed throughout the study.
Assessments
The patients were evaluated at baseline and at weeks 2 
and 4 after treatment. The primary efficacy end point was 
the change from baseline in local eczema area and se-
verity index (EASI) score of the trunk on day 288,9. The 
secondary end points were the changes patient global as-
sessment (PGA) and itch visual analogue scale (VAS) score 
of trunk from baseline to day 28. In addition, changes in 
local EASI, PGA and itch VAS score of the trunk during 
the study period were compared with those of non-truncal 
areas (head, neck and extremities). All adverse events dur-
ing the investigation period were recorded.
Changes in overall clinical status were rated in accord-
ance with the patient’s global assessment scores based on 
a 5-point scale defined by a score of 0 (clear), 1 (almost 
clear), 2 (mild), 3 (moderate), 4 (severe), or 5 (very severe). 
The patients were also asked to assess pruritus by using an 
itch VAS score, where 0 indicated no itching sense and 10 
indicated the worst itch imaginable.
Local EASI, PGA and itch VAS scores of the trunk and 
non-truncal areas were evaluated simultaneously in the 
study. Local EASI score of the each body region in this 
study was defined as multiplying the sum of the severity 
scores for each symptom by the area score and then multi-
plying the result by a constant weighted value assigned to 
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Table 2. Changing in efficacy parameters on trunk and non-truncal areas at baseline, week 2, and week 4
Efficacy parameter Trunk Non-truncal areas p-value
Local eczema area and severity index score
  Baseline 4.71±4.03 7.91±6.75 N/A
  Week 2 3.01±3.41 5.33±6.06 ＜0.001
  Week 4  2.2±3.34 3.98±5.85 ＜0.001
Patient global assessment score
  Baseline 2.96±1.07 3.10±0.97 N/A
  Week 2 2.14±1.08 2.39±1.04 ＜0.001
  Week 4 1.71±1.15 1.88±1.10 ＜0.001
Itch visual analogue scale score
  Baseline 5.15±2.47 5.67±2.23 N/A
  Week 2 3.44±2.29 3.89±2.21 ＜0.001
  Week 4 2.61±2.19 3.16±2.32 ＜0.001
p-values in comparison with baseline (paired Wilcoxon test). N/A: not applicable.
Table 1. Demographics of the patients and causes of drop out
(n=291)
Demographic Value
Demographics of patients who completed the study (n=176)
  Gender
    Male 99 (56.3)
    Female 77 (43.8)
  Age (yr) 18.3±10.4
  Age group
    ≥19 years 83 (47.2)
    ＜19 years 93 (52.8)
  Baseline eczema area and severity index score
    Overall 12.62±10.03
    ≥19 years 14.86±11.72
    ＜19 years 10.62±7.77
Causes of drop out (n=115)
  Causes 
    Simple follow-up loss 103 (89.6)
    Voluntary withdrawal 5 (4.3)
    Lack of efficacy 4 (3.5)
    Adverse events 2 (1.7)
    Aggravated atopic dermatitis symptoms 1 (0.9)
Values are presented as number (%) or mean±standard
deviation.
that body region, so the sum of each local EASI score of 
trunk and non-truncal areas was equal to patient’s EASI 
score. Local PGA score and itch VAS score of the trunk 
were also obtained from the patients’ subjective assess-
ments, which were localized to the trunk. All adverse 
events, including burning sensation, itching sensation, er-
ythema, aggravation of skin lesion, skin infection, and oth-
er localized and systemic adverse events during the inves-
tigation period were recorded.
Statistical analysis
All statistical analyses were performed by using IBM SPSS 
Statistics ver. 21.0 (IBM Co., Armonk, NY, USA). We used 
the paired Wilcoxon test for analysis of primary and sec-
ondary end points, and Mann-Whitney test was used to 
compare changing in local EASI, PGA and itch VAS score 
of the trunk with those of non-truncal areas. The p-values 
of ＜0.05 were considered statistically significant.
RESULTS
Demographics
For this study, 291 patients were recruited and 176 pa-
tients (99 males and 77 females; mean age, 18.3 years; 
range, 2∼59 years) completed the full 4-week treatment 
course. Eighty-three patients were aged ≥19 years, while 
93 patients were aged ＜19 years. The mean baseline 
EASI scores of all the patients who completed the study, 
the patients aged ≥19 years, and the patients aged ＜19 
years were 12.62±10.03, 14.86±11.72, and 10.62±7.77, 
respectively. During the clinical trials, 115 patients did not 
complete the study for several reasons. The most common 
cause of discontinuation was simple follow-up loss 
(n=103, 89.6%), followed by voluntary withdrawal (n=5, 
4.3%), lack of efficacy (n=4, 3.5%), adverse events (n=2, 
1.7%), and aggravated AD symptoms (n=1, 0.9%) (Table 1).
Efficacy
Statistical clinical improvements in both the trunk and 
non-truncal areas were observed over the treatment 
period. By the end of the treatment period, the mean EASI 
score of the whole body (6.19±8.91) was statistically im-
proved from the baseline (12.62±10.03), while the mean 
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Fig. 1. The rate of improvements in local eczema area and severity 
index (EASI), patient global assessment (PGA) and itch visual ana-
logue scale (VAS) score of trunk from baseline to week 4 (53.3%, 
42.2%, 49.3%, respectively) was significantly higher than those 
of the non-truncal areas (49.7%, 39.4%, 44.3%, respectively). 
*The rate of improvements in each parameter in comparison 
with week 4 and baseline. †,‡Statistically significant difference 
between trunk and non-truncal areas, †p＜0.001, ‡p＜0.05 
(Mann-Whitney test).
Table 3. Incidence of adverse events of topical tacrolimus during
the study period (n=176)
Adverse events Week 2 Week 4
Burning sensation 17 (9.7) 12 (6.8)
Itching sensation 8 (4.5) 4 (2.3)
Localized erythema 1 (0.6) 1 (0.6)
Folliculitis 1 (0.6) 0 (0)
Values are presented as number (%).
local EASI score of the trunk (2.2±3.34) and non-truncal 
areas (3.98±5.85) was also significantly decreased from 
those at baseline (4.71±4.03 and 7.91±6.75, respectively). 
The mean PGA score of the trunk (1.71±1.15) and 
non-truncal areas (1.88±1.10) at week 4 were notably im-
proved from those at baseline (2.96±1.07 and 3.10±0.97, 
respectively). The mean itch VAS score of the trunk 
(2.61±2.19) and non-truncal areas (3.16±2.32) were also 
profoundly decreased from those at baseline (5.15±2.47 
and 5.67±2.23, respectively) (Table 2). In addition, the 
rate of improvement in mean local EASI, PGA and itch 
VAS score of the trunk from those at baseline were statisti-
cally higher than those of non-truncal areas (53.3% vs. 
49.7%, 42.2% vs. 39.4% and 49.3% vs. 44.3%, respectively 
(Fig. 1).
Safety
Adverse events were monitored by the investigators at 
each visit by history taking and physical examination. No 
serious adverse events were observed, except local re-
actions, including burning sensation, itching sensation, lo-
calized erythema, and folliculitis (Table 3). In the group of 
patients who completed the 4-week study course, a burn-
ing sensation was observed in 9.7% (n=17) of the patients 
at week 2 and in 6.8% (n=12) at week 4. Itching sensa-
tion was observed in 4.5% (n=8) of the patients at week 2 
and in 2.3% (n=4) at week 4. Localized erythema and fol-
liculitis were observed only in one patient, respectively. 
As the results, incidence of burning and itching sensation 
of topical tacrolimus tended to decrease as the study 
progressed. Only two (0.7%) of the 291 patients were 
dropped out of the study because of adverse events due to 
topical tacrolimus. One had both burning and itching sen-
sations, and the other had only itching sensation. No sys-
temic symptoms were observed during the 4-week study 
period. 
DISCUSSION
Topical tacrolimus is an effective anti-inflammatory ther-
apy for acute and chronic states of AD in both adults and 
children1-4. It is usually applied to sensitive areas such as 
the face, anogenitals, and skin folds of neck and ex-
tremities, where the adverse risk from topical cortico-
steroids is higher3. Several reports support its usefulness as 
steroid-sparing agent in the case of recalcitrant AD to top-
ical corticosteroids, corticosteroid-induced skin atrophy, 
and long-term use of uninterrupted topical corticoste-
roids10-12.
Many AD patients experience aggravated symptoms in the 
trunk and other body parts such as face and flexural areas, 
and physicians are familiar with using topical cortico-
steroids to the truncal area4,13. The usefulness of topical ta-
crolimus for the truncal area in AD patients tends to be 
overlooked for some reasons as follows. First, the large 
body surface area over the trunk can be a burden to physi-
cians because of systemic absorption of tacrolimus. Second, 
AD patients’ adherence to treatment for the truncal area 
could be lower than that for other body parts because of 
reasons such as large surface of the trunk itself and diffi-
culties of applying14. The tacrolimus ointment also some-
times could feel unpleasant because it easily stains cloth-
ing and interferes with daily activities15. In addition, lack 
of clinical evidence for the efficacy and safety of topical 
tacrolimus to the trunk could make physicians hesitate to 
use topical tacrolimus. Many studies reported the efficacy 
and safety of topical tacrolimus in the treatment of AD, 
but no report has focused on the efficacy and safety of top-
ical tacrolimus to the trunk itself, and topical steroids are 
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still the mainstay of AD treatment, especially to the 
trunk1-4.
In our study, we focused on the efficacy of topical tacroli-
mus to the trunk comparing with non-truncal areas. Local 
EASI, PGA, and itch VAS score examined in this study 
demonstrated that topical tacrolimus is not only effective 
to the facial or flexural area but also the trunk. The rate of 
improvement in all the parameters showed even better on 
the trunk than on the non-truncal areas. Overestimation of 
the efficacy based on the local PGA and itch VAS scores 
could be possible because both PGA and itch VAS scores 
are subjective symptoms of patients and, the trunk is a less 
exposed area than the other body parts such as the face 
and flexural area. However, in our study, the rate of im-
provement in local EASI score was also better on the trunk 
comparing non-truncal areas.
Although any adherence profile was not imposed on pa-
tients to complete the study, we obtained enough results 
to prove the efficacy of topical tacrolimus to the trunk. It 
can be meaningful for physicians who worry about low 
adherence of topical tacrolimus to the trunk in AD pa-
tients14-16.
Treatment with topical tacrolimus was generally well 
tolerated. Only two of the 291 patients (0.7%) dis-
continued the study because of adverse events. The ad-
verse events were limited to local reactions, including 
burning sensation, followed by itching sensation, eryth-
ema, and folliculitis. Leung et al.2 stated that topical tacro-
limus applied on up to 100% of the body surface in adults 
and children have shown no significant systemic adverse 
effects. Cury Martins et al.17 also concluded the systemic 
safety of topical tacrolimus in their review article with 
5,885 participants, as systemic absorption was rarely de-
tectable, only in low levels, and this decreased with time. 
Recently, the importance of proactive treatment of AD has 
been highlighted18,19. However, most patients might hesi-
tate to use topical corticosteroids to the trunk as a proac-
tive treatment because of several severe side effects after 
systemic corticosteroids absorption, such as Cushing syn-
drome due to the large surface area of the trunk20,21. 
Charman et al.22 reported 72.5% of adult AD patients or 
parents children with AD had admitted to being worried 
about using topical corticosteroids. Based on our results, 
topical tacrolimus can be a good option for proactive 
treatment in AD patients with corticosteroids phobia23.
The limitations of our research are as follows: Our re-
search was an observational study, so we could not com-
pare the effectiveness of topical tacrolimus with other 
treatments for the truncal area in AD patients. 
In summary, this study showed that topical tacrolimus 
seems to be effective and safe for treating truncal AD. We 
believe our study could be informative for many physi-
cians who hesitate to use topical tacrolimus on the trunk 
because of the lack of clinical evidence for efficacy and 
safety.
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